Millennium Bug Could Bite HCFA

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

WASHINGTON-Whether you call it the Year 2000 Problem (Y2K) or the Millennium Bug, it could bite the Department of Health and Human Services (HHS) quite badly, a congressional report warns. The Y2K problem stems from the fact that most computers still use only two digits to represent the year. Come the year 2000, unless this flaw is corrected, these computers will read 00 as the year 1900, and chaos will occur in their calculations.

WASHINGTON—Whether you call it the Year 2000 Problem (Y2K) or the Millennium Bug, it could bite the Department of Health and Human Services (HHS) quite badly, a congressional report warns. The Y2K problem stems from the fact that most computers still use only two digits to represent the year. Come the year 2000, unless this flaw is corrected, these computers will read 00 as the year 1900, and chaos will occur in their calculations.

In his sixth “report card” on the efforts of the federal organizations to correct their computers, Rep. Steven Horn (R-Calif) gave HHS an “F,” largely because of the failure of the Health Care Financing Administration (HCFA) to update its computers. Overall, he gave the federal effort a “D” grade.

“We estimate, at the current rate of progress, that nearly one-third of the federal government’s mission-critical systems will not be Year 2000 compliant by the deadline established by the President of March 30, 1999,” Rep. Horn said.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content